1. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010;122:1–23. PMID:
20655178.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223. PMID:
16172203.
3. Buckley PF. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008;69(Suppl 1):4–17.
4. Henderson DC. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. J Clin Psychiatry 2008;69:e04PMID:
18363448.
5. American Diabetes Association. American Psychiatric Association. American Association of Clinical Endocrinologists North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res 2004;12:362–368. PMID:
14981231.
6. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007;68(Suppl 6):10–13. PMID:
17650054.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington DC: American Psychiatric Association; 1994.
8. Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001;55(Suppl 44):5–69. PMID:
11860666.
9. Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 2009;24:229–238. PMID:
19531959.
10. Ballas C, Yang C, O'Reardon J, Ballas P, Baldassano C. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004;4:179–186. PMID:
15853558.
11. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(Suppl 19):6–12.
12. Lublin H, Haug HJ, Koponen H, Sigmundsson T. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry 2009;10:710–718. PMID:
18803070.
13. Rossi A, Vita A, Tiradritti P, Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008;23:216–222. PMID:
18545060.
14. Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol 2010;33:121–125. PMID:
20502130.
15. Stip E, Zhornitsky S, Potvin S, Tourjman V. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:997–1000. PMID:
20470848.
16. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818–825. PMID:
15121646.
17. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007;22:249–267. PMID:
17690594.
18. Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:383–388. PMID:
17129654.
19. Sorensen TI. Obesity defined as excess storage of inert triglycerides--do we need a paradigm shift? Obes Facts 2011;4:91–94. PMID:
21577014.
20. Gaysinskaya VA, Karatayev O, Chang GQ, Leibowitz SF. Increased caloric intake after a high-fat preload: relation to circulating triglycerides and orexigenic peptides. Physiol Behav 2007;91:142–153. PMID:
17383691.
21. Malmlof K, Golozoubova V, Peschke B, Wulff BS, Refsgaard HH, Johansen PB, et al. Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity (Silver Spring) 2006;14:2154–2162. PMID:
17189541.
22. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595–600. PMID:
14624190.
23. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;CD006627PMID:
19821380.
24. Na KS, Kim WH, Jung HY, Ryu SG, Min KJ, Park KC, et al. Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:295–300. PMID:
22796278.